Referred to the House Committee on Energy and Commerce.

Original title: “HRES 1561: Expressing support for the designation of the third week of September as "Fungal Disease Awareness Week" and encouraging efforts to improve awareness, diagnosis, treatment, surveillance, and prevention of fungal diseases in the United States.”

Referred to the House Committee on Energy and Commerce.

Original title: “HRES 1558: Expressing the sense of the House of Representatives that, to maintain the health care safety net, Federally Qualified Health Centers should continue to operate under their longstanding single patient definition for delivery of all services, including prescription drugs.”

Read twice and referred to the Committee on Homeland Security and Governmental Affairs.

Original title: “S 5433: Wildland Firefighter Health and Safety Act”

The Food and Drug Administration (FDA) is publishing an order setting forth its final determination regarding a partial exemption from the premarket notification requirements for radiology computer- aided detection and/or diagnosis devices and computer-aided triage and notification devices that was the subject of a notice published in the Federal Register of December 29, 2025. That notice announced FDA's receipt of a petition that requested exemption from the premarket notification requirements

Original title: “Medical Devices; Exemption From Premarket Notification: Radiology Computer-Aided Detection and/or Diagnosis Devices and Computer-Aided Triage and Notification Devices”

Referred to the Committee on Natural Resources, and in addition to the Committees on Agriculture, and Education and Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Original title: “HR 10492: Wildland Firefighter Health and Safety Act”

Referred to the Committee on Energy and Commerce, and in addition to the Committees on Transportation and Infrastructure, Agriculture, Natural Resources, and Science, Space, and Technology, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Original title: “HR 10488: Environmental Health Restoration Act of 2026”

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Recommendations for the Development of Blood Collection, Processing, and Storage Systems for the Manufacture of Blood Components Using the Buffy Coat Method." The guidance document provides recommendations on the development of blood collection, processing, and storage systems (e.g., blood bags with anticoagulant and additive solutions, empty bags for platelet pooling) intended for the man

Original title: “Recommendations for the Development of Blood Collection, Processing, and Storage Systems for the Manufacture of Blood Components Using the Buffy Coat Method; Guidance for Industry; Availability”

Read twice and referred to the Committee on Finance.

Original title: “S 5443: Health Infrastructure Security and Accountability Act of 2026”

Read twice and referred to the Committee on Finance.

Original title: “S 5424: Community Health Worker Access Act”

The Office of Community Services (OCS), Administration for Children and Families (ACF), Department of Health and Human Services, is proposing to continue to collect data to understand diaper need and outcomes for beneficiaries of the Diaper Distribution Demonstration and Research Pilot (DDDRP). This collection (Office of Management and Budget (OMB) #: 0970-0642) currently includes the Beneficiary Report and Beneficiary Survey. No changes are proposed to the Beneficiary Report. OCS is proposing r

Original title: “Proposed Information Collection Activity; Diaper Distribution Demonstration and Research Pilot Beneficiary and Organizational Survey and Beneficiary Report”

After reviewing Bausch & Lomb’s response to its observations, the FDA questioned whether the company is committed to implementing significant design remediations.

Original title: “FDA warning letter accuses Bausch & Lomb of lacking commitment to remediation”

Information on how to submit specimens to CDC for laboratory diagnosis of rickettsial diseases.

Original title: “Submitting Specimens for Rickettsiosis Tests”

This notice announces the annual adjustment in the amount in controversy (AIC) threshold amounts for Administrative Law Judge (ALJ) hearings and judicial review under the Medicare appeals process. The adjustment to the AIC threshold amounts will be effective for requests for ALJ hearings and judicial review filed on or after January 1, 2027. The calendar year 2027 AIC threshold amounts are $200 for ALJ hearings and $2,000 for judicial review.

Original title: “Medicare Program; Medicare Appeals; Adjustment to the Amount in Controversy Threshold Amounts for Calendar Year 2027”

Referred to the Committee on Energy and Commerce, and in addition to the Committees on Natural Resources, Agriculture, and Transportation and Infrastructure, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Original title: “HR 10425: Environmental Health Restoration Act of 2026”

The NIH Intramural Research Program (IRP) relies on a trustworthy research record to sustain public confidence and advance public health. NIH maintains procedures in compliance with NIH policy and 42 CFR part 93 to evaluate allegations of research misconduct, including falsification, fabrication, and plagiarism, through a fair, consistent, and peer-informed process. The proposed web-based reporting form will help the Agency Intramural Research Integrity Officer (AIRIO) receive sufficient informa

Original title: “Proposed Collection; 60-Day Comment Request; NIH Intramural Reporting of Research Misconduct (IRRM) Web Form (Office of the Director/Office of Intramural Research)”

The Centers for Disease Control and Prevention (CDC), a component of the Department of Health and Human Services (HHS), announces it is issuing an Order under Sections 362 and 365 of the Public Health Service Act, and associated implementing regulations, continuing the suspension of the right to introduce certain persons from countries where an outbreak of a quarantinable communicable disease exists. This Order was issued on September 11 and shall remain in effect through 4:59 p.m. Eastern Dayli

Original title: “Order Under Sections 362 and 365 of the Public Health Service Act Continuing the Suspension of the Right To Introduce Certain Persons From Countries Where a Quarantinable Communicable Disease Exists”

The National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is giving notice of the invention listed below, which is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies

Original title: “Government-Owned Inventions; Availability for Licensing”

This notice announces the second biannual Healthcare Common Procedure Coding System (HCPCS) Level II public meeting of 2026 to discuss the CMS preliminary coding, Medicare benefit category, and Medicare payment determinations, if applicable, for new revisions to the HCPCS Level II code set for non-drug and non-biological items and services, as well as how to register for the meeting.

Original title: “Medicare Program; Public Meeting for New Revisions to the Healthcare Common Procedure Coding System (HCPCS) Level II Coding”

The Office of Research Integrity (ORI) announces an ongoing opportunity for non-federal public and private sector entities to co- sponsor conferences, workshops, symposia, meetings, roundtables, or other similar events (collectively, "Events") with ORI. ORI co- sponsors a limited number of Events with non-federal entities each year. Potential co-sponsors must have demonstrated interest and experience in the responsible conduct of research or handling allegations of research misconduct and must b

Original title: “Opportunity To Co-Sponsor Events With the Office of Research Integrity”